Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allergies
Biotech
Lycia aims for $228M IPO to advance food allergy rival to Xolair
Lycia is banking on a $227.8 million IPO as the biotech seeks to finance its protein degraders for autoimmune, inflammatory and allergic diseases.
James Waldron
Oct 20, 2026 10:52am
Lilly inks $2.88B Merida buyout to expand autoimmune pipeline
Aug 31, 2026 9:18am
Novartis pens $2B deal for biotech with potential Xolair successor
Mar 27, 2026 4:46am
GSK pays $2.2B to buy Rapt for food allergy challenger to Xolair
Jan 20, 2026 4:37am
Vaccine protects mice from allergic reactions for a year
Apr 17, 2025 1:04pm
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
